1.Hochuekkito Efficacy in Late-Onset Hypogonadism (LOH) Patients
Tomoka KUMAMOTO ; Shinichi HISASUE ; Mitsuko YASUDA ; Hisamitsu IDE ; Toshiyuki CHINA ; Masahiro INOUE ; Keisuke SAITO ; Shuji ISOTANI ; Raizo YAMAGUCHI ; Satoru MUTO ; Shigeo HORIE
Kampo Medicine 2013;64(3):160-165
The purpose of this study is to evaluate the efficacy of hochuekkito for late-onset hypogonadism (LOH) patients. We administered hochuekkito 7.5 g/day for 8 weeks to 47 patients with LOH whose AMS scale was more than 27. We assessed the patients' symptom change with the AMS, SHIM, SDS, BDI, and SF-36. We measured their endocrine profiles and levels of their cytokines. At the end of study, 31 of 47 patients were evaluable. No significant difference in subjective symptoms was seen with any questionnaire after 8 weeks hochuekkito administration. However, hochuekkito significantly increased free testosterone and decreased ACTH/cortisol levels. Thus we believe hochuekkito is beneficial for the treatment of LOH.
2.Clinical Usefulness of Corticotropin Releasing Hormone Testing in Subclinical Cushing's Syndrome for Predicting Cortisol Replacement after Adrenalectomy.
Masahiro INOUE ; Hisamitsu IDE ; Koji KURIHARA ; Tatsuro KOSEKI ; Jingsong YU ; Toshiyuki CHINA ; Keisuke SAITO ; Shuji ISOTANI ; Satoru MUTO ; Shigeo HORIE
Korean Journal of Urology 2012;53(6):414-418
PURPOSE: The purpose of this study was to investigate the clinical and hormonal features of patients with incidentally discovered adrenal adenomas in relation to corticotropin releasing hormone (CRH) testing and the clinical outcome of adrenalectomy. MATERIALS AND METHODS: Twenty-three consecutive patients with incidentally detected adrenal adenomas were included in this retrospective study. All the patients underwent abdominal computed tomography scans and hormonal assays, including assessment of circadian rhythms of plasma cortisol and corticotropin (adrenocorticotropic hormone, ACTH), a corticotropin stimulation test, and low-dose and high-dose dexamethasone tests. The patients were reevaluated at regular intervals (6, 12, and 24 months) for a median period of 24 months. Subclinical Cushing's syndrome (SCS) was diagnosed in patients with subtle hypercortisolism who did not present clinical signs of Cushing's syndrome. RESULTS: We calculated the responsive index (peak value of ACTH in CRH test/baseline value of ACTH in CRH test). Of 23 patients, 6 had Cushing's syndrome, 8 had SCS, and 9 had a non-functioning tumor. All patients underwent laparoscopic adrenalectomy. Several patients (5 of 6 with Cushing's syndrome and 2 of 8 with SCS) required cortisol replacement therapy after surgery. The remaining patients required no hormonal replacement after surgery. Those who required hormone replacement had a responsive index of less than 1.2. Those who did not need hormone replacement therapy had a responsive index of more than 2.0. CONCLUSIONS: In our limited experience, the responsive index of the CRH test might be a valuable tool for predicting the need for cortisol replacement after surgery in patients with SCS.
Adenoma
;
Adrenalectomy
;
Adrenocorticotropic Hormone
;
Circadian Rhythm
;
Corticotropin-Releasing Hormone
;
Cushing Syndrome
;
Dexamethasone
;
Hormone Replacement Therapy
;
Humans
;
Hydrocortisone
;
Plasma
;
Retrospective Studies